NYSE:BMYPharmaceuticals
Should FDA Breakthrough Therapy Status for Iza-Bren Shift Long-Term Expectations for Bristol Myers Squibb (BMY)?
Earlier this month, SystImmune Inc. and Bristol Myers Squibb announced that the FDA had granted Breakthrough Therapy Designation to izalontamab brengitecan (iza-bren) for certain advanced non-small cell lung cancer patients who have progressed after EGFR TKI and platinum-based chemotherapy.
This designation highlights the potential of iza-bren as a first-in-class bispecific antibody-drug conjugate targeting EGFR and HER3, based on efficacy and safety results from ongoing multinational...